Reduced Costs and Continued Cures Act
Latest action · Nov 1, 2022 Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedSep 14, 2021
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Reduced Costs and Continued Cures Act
This bill establishes and alters several programs and requirements relating to the prices of prescription drugs.
For example, the bill establishes and alters several requirements under Medicare and Medicaid, including
- requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation,
- capping annual out-of-pocket spending under the Medicare prescription drug benefit, and
- increasing the maximum rebate amount under the Medicaid Drug Rebate Program.
The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including
- authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics,
- limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and
- nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.
Cosponsors 5
Members who signed on, in the order they did. Signatures ran from Sep 14, 2021 to Sep 20, 2021; 4 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | J. Luis Correa | Original | Sep 14, 2021 |
| D-NY | Kathleen M. Rice | Original | Sep 14, 2021 |
| D-OR | Kurt Schrader | Original | Sep 14, 2021 |
| D-FL | Stephanie N. Murphy | Original | Sep 14, 2021 |
| D-NJ | Josh Gottheimer | Sep 20, 2021 |
Committees 3
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Sep 14, 2021 |
| Health Subcommittee | Referred Sep 15, 2021 | |
| House | Ways and Means Committee | Referred Sep 14, 2021 |
| Health Subcommittee | Referred Sep 14, 2021 | |
| House | Judiciary Committee | Referred Sep 14, 2021 |
| Administrative State, Regulatory Reform, and Antitrust Subcommittee | Referred Nov 1, 2022 | |
| Courts, Intellectual Property, Artificial Intelligence, and the Internet Subcommittee | Referred Nov 1, 2022 |
Actions 6
Everything that happened, newest first.
- Nov 1, 2022Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- Nov 1, 2022Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
- Sep 15, 2021Referred to the Subcommittee on Health.
- Sep 14, 2021Introduced in House
- Sep 14, 2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 167, no. 158, September 14, 2021, page H4524.
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R47872 | Medicare Drug Price Negotiation Under the Inflation Reduction Act: Industry Responses and Potential Effects | Report | Dec 8, 2023 |
| R47267 | Patents and Innovation Policy Archived | Report | Oct 3, 2022 |
Related bills 10
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1428 | Preserve Access to Affordable Generics and Biosimilars Act | Related bill | Dec 9, 2021 |
| S 1435 | Affordable Prescriptions for Patients Act of 2021 | Related bill | Jul 29, 2021 |
| S 2327 | Seniors Prescription Drug Relief Act | Related bill | Jul 13, 2021 |
| HR 2706 | Freedom from Price Gouging Act | Related bill | Apr 21, 2021 |
| HR 2855 | Star Rating for Biosimilars Act | Related bill | Apr 27, 2021 |
| HR 2873 | Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 | Related bill | Sep 29, 2021 |
| HR 2884 | Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act | Related bill | Sep 30, 2021 |
| HR 2891 | Preserve Access to Affordable Generics and Biosimilars Act | Related bill | Sep 29, 2021 |
| HR 4417 | Capping Drug Costs for Seniors Act of 2021 | Related bill | Jul 14, 2021 |
| HR 5237 | Reduced Costs and Continued Cures Act of 2021 | Related bill | Nov 1, 2022 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes.
- Short Title(s) as Introduced
- Reduced Costs and Continued Cures Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Accounting and auditing
- Administrative law and regulatory procedures
- Administrative remedies
- Appropriations
- Civil actions and liability
- Competition and antitrust
- Congressional oversight
- Consumer affairs
- Contracts and agency
- Department of Health and Human Services
- Digestive and metabolic diseases
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Federal Trade Commission (FTC)
- Genetics
- Government studies and investigations
- Health
- Health care costs and insurance
- Health care coverage and access
- Health care quality
- Health programs administration and funding
- Health technology, devices, supplies
- Home and outpatient care
- Inflation and prices
- Intellectual property
- Intergovernmental relations
- Judicial review and appeals
- Licensing and registrations
- Manufacturing
- Marketing and advertising
- Medicaid
- Medicare
- Performance measurement
- Prescription drugs
- Public contracts and procurement
- State and local government operations
Text 1
Each version as it was printed, newest first.
- Sep 14, 2021Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
